Monika Kutyna

Research Interests

Cancer Cell Biology Cancer Genetics Medical and Health Sciences Cancer Biology and Clinical Oncology Translational Health Outcomes

Mrs Monika Kutyna

School of Medicine

College of Health

I am an early career postdoctoral researcher with an emerging track record, on a trajectory to establish myself as an independent investigator in the field of bone marrow microenvironment research. My project focuses on the role of bone marrow microenvironment in the pathogenesis of myeloid neoplasms where I developed complex in vtiro assays to study mesenchymal stromal cell (MSC) and drug targeting using primary cells. I also established a repository of biospecimens (MSC, bone marrow and blood mononuclear cells) from patients with myeloid neoplasms and age-matched controls. I am also instrumental in contributing to the South Australian Myeloid Neoplasms (SA-MN) Registry by correlating experimental data with patient clinical information (i.e. treatment history, family history) and outcomes.

Therapy-related myeloid neoplasms (t-MN) are poorly understood blood cancers associated with extremely poor clinical outcomes causing early death in otherwise long-term cancer survivors. It accounts for ~20% of cases of myeloid neoplasms and is expected to rise by 2035 due to the increased use of chemotherapy and improved survival of cancer patients (Leukemia Foundation).The current paradigm ignores the contribution of aberrant bone marrow microenvironment and myeloid neoplasms are considered primarily to be haematopoietic stem cells (HSC) autonomous disorders, in which initiation and progression are mainly driven by HSC intrinsic genetic events.

Therefore, my project focuses on the role of bone marrow microenvironment in the pathogenesis of myeloid neoplasms, speciffically t-MN,  where I developed complex in vtiro assays to study mesenchymal stromal cell (MSC) and drug targeting using primary cells. I also established a repository of biospecimens (MSC, bone marrow and blood mononuclear cells) from patients with myeloid neoplasms and age-matched controls. 

Date Position Institution name
2024 - ongoing Affiliate Associate Lecturer University of Adelaide
2022 - ongoing Postdoctoral Researcher South Australian Health and Medical Research Institute
2022 - ongoing Postdoctoral Researcher Central Adelaide Local Health Network

Language Competency
English Can read, write, speak, understand spoken and peer review
Polish Can read, write, speak, understand spoken and peer review

Date Institution name Country Title
2017 - 2022 University of Adelaide Australia PhD

Year Citation
2025 Wiseman, T., Spooner, M., Khanna, S., Hung, K., Toop, C., Kutyna, M. M., . . . Hiwase, D. K. (2025). RBC Transfusion Dependency Refines the Molecular International Prognostic Scoring System for Myelodysplastic Syndrome. Blood Advances, 9(16), 4244-4247.
DOI Scopus2 Europe PMC2
2025 Shah, M. V., Hung, K., Baranwal, A., Wechalekar, G., Al-Kali, A., Toop, C. R., . . . Hiwase, D. (2025). Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer Journal, 15(1), 88-1-88-11.
DOI Scopus2 WoS2 Europe PMC1
2025 Kok, C. H., Al-Kali, A., Thomas, D., He, R., Kutyna, M. M., Alkhateeb, H. B., . . . Hiwase, D. K. (2025). RAS Mutation Identifies a Poor Prognostic Molecular Subtype of Therapy-Related Myeloid Neoplasm. Blood Advances, 9(15), 3814-3818.
DOI
2025 Shah, M. V., Hung, K., Baranwal, A., Kutyna, M. M., Al-Kali, A., Toop, C., . . . Hiwase, D. K. (2025). Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Advances, 9(13), 3370-3380.
DOI Scopus6 WoS4 Europe PMC5
2025 Gharaee, N., Wegrzyn-Woltosz, J., Jiang, J., Akhade, V. S., Bridgers, J., Stubbins, R. J., . . . Karsan, A. (2025). Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm: MECHANISMS OF RESISTANCE. Leukemia, 39(4), 917-928.
DOI Scopus1 WoS1 Europe PMC1
2024 Hong, L. E., Wechalekar, M. D., Kutyna, M. M., Small, A., Lim, K., Thompson-Peach, C. A., . . . Hiwase, D. K. (2024). IDH-Mutant Myeloid Neoplasms are Associated with Seronegative Rheumatoid Arthritis and Innate Immune Activation. Blood, 143(18), 1873-1877.
DOI Scopus11 WoS11 Europe PMC10
2024 Wechalekar, M. D., Zhao, L. -P., Kutyna, M. M., Hong, L. E., Li, J., Hung, K., . . . Hiwase, D. K. (2024). Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features. Blood Cancer Journal, 14(1), 116-1-116-5.
DOI Scopus1 WoS1 Europe PMC1
2024 Lim, K., Kan, W. L., Nair, P. C., Kutyna, M., Lopez, A. F., Hercus, T., . . . Thomas, D. (2024). CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting. PLoS One, 19(9), e0310641-1-e0310641-19.
DOI Scopus1 Europe PMC1
2024 Singhal, D., Kutyna, M. M., Hahn, C. N., Shah, M. V., & Hiwase, D. K. (2024). Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment. BLOOD CANCER DISCOVERY, 5(6), 400-416.
DOI Scopus12 WoS12 Europe PMC9
2023 Thomas, D., Wu, M., Nakauchi, Y., Zheng, M., Thompson-Peach, C. A., Lim, K., . . . Majeti, R. (2023). Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability. Cancer Discovery, 13(2), 496-515.
DOI Scopus47 WoS43 Europe PMC46
2023 Kutyna, M. M., Loone, S., Saunders, V. A., White, D. L., Kok, C. H., & Hiwase, D. K. (2023). Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. International Journal of Molecular Sciences, 24(4), 3553-1-3553-14.
DOI Scopus3 WoS3 Europe PMC3
2023 Hiwase, D. K., Hahn, C. N., Tran, E. N. H., Chhetri, R., Baranwal, A., Al-Kali, A., . . . Shah, M. V. (2023). TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood, 141(9), 1087-1091.
DOI Scopus30 WoS26 Europe PMC26
2023 Eadie, L. N., Rehn, J. A., Schutz, C. E., Heatley, S. L., Kutyna, M. M., Hiwase, D. K., . . . Yeung, D. T. (2023). Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling. British Journal of Haematology, 203(2), 282-287.
DOI Europe PMC1
2023 Sharplin, K., Proudman, W., Chhetri, R., Tran, E. N. H., Choong, J., Kutyna, M., . . . Hiwase, D. (2023). A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World Data. Cancers, 15(16), 1-14.
DOI Scopus4 WoS4 Europe PMC3
2022 Kutyna, M. M., Kok, C. H., Lim, Y., Campbell, D., Paton, S., Thompson-Peach, C. A. L., . . . Hiwase, D. (2022). Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm. Blood, 140(Supplement 1), 9755-9756.
DOI
2022 Kutyna, M. M., Kok, C. H., Lim, Y., Tran, E. N. H., Campbell, D., Paton, S., . . . Hiwase, D. K. (2022). A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia, 36(11), 2678-2689.
DOI Scopus17 WoS17 Europe PMC17
2022 Shah, M., Hahn, C. N., Tran, E. N. H., Sharplin, K. M., Chhetri, R., Baranwal, A., . . . Hiwase, D. (2022). <i>TP53</i> Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome. BLOOD, 140(Supplement 1), 9798-9799.
DOI WoS2
2021 Singhal, D., Hahn, C. N., Feurstein, S., Wee, L. Y. A., Moma, L., Kutyna, M. M., . . . Hiwase, D. K. (2021). Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer. Leukemia, 35(11), 3245-3256.
DOI Scopus48 WoS46 Europe PMC44
2020 Kutyna, M. M., Wee, L. Y. A., Paton, S., Cakouros, D., Arthur, A., Chhetri, R., . . . Hiwase, D. K. (2020). Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair. Blood, 136(Supplement 1), 37-38.
DOI
2019 Chhetri, R., Wee, L. Y. A., Sinha, R., Kutyna, M. M., Pham, A., Stathopoulos, H., . . . Hiwase, D. K. (2019). Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: Prevalence, characteristic and significance. Haematologica, 104(10), E451-E454.
DOI Scopus18 WoS18 Europe PMC12
2019 Singhal, D., Wee, L. Y. A., Kutyna, M. M., Chhetri, R., Geoghegan, J., Schreiber, A. W., . . . Hiwase, D. K. (2019). The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia, 33(12), 2842-2853.
DOI Scopus50 WoS48 Europe PMC44
2017 Hiwase, D., Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., . . . Germing, U. (2017). Dynamic assessment of RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients. American Journal of Hematology, 92(6), 508-514.
DOI Scopus35 WoS31 Europe PMC27
2017 Singhal, D., Kutyna, M. M., Chhetri, R., Wee, L. Y. A., Hague, S., Nath, L., . . . Hiwase, D. K. (2017). Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Haematologica, 102(12), 2021-2029.
DOI Scopus49 WoS42 Europe PMC35
2014 Hiwase, D. K., Hahn, C. N., Babic, M., Moore, S., Butcher, C. M., Kutyna, M. M., . . . Scott, H. S. (2014). Clonal Diversity of Recurrently Mutated Genes in Myelodysplastic Syndromes. BLOOD, 124(21), 3 pages.

Year Citation
2024 Kamel, M. M., Robinson, N., Kutyna, M., Lim, K., Thompson-Peach, C., Lane, S. W., . . . Thomas, D. (2024). High Dose Ascorbate Reduces Interleukin-1 Beta Secretion in TET2 Mutant Monocytes and Demonstrates Excellent and in CMML Patients in Combination with Azacitidine. In BLOOD Vol. 144 (pp. 1817-1818). ELSEVIER.
DOI WoS2
2024 Kutyna, M., Thomas, D., & Hiwase, D. (2024). Impact of Chronic Inflammation and Cytotoxic Therapy on Bone Marrow Microenvironment of Patients with Autoimmune Rheumatic Diseases and Myeloid Neoplasms. In BLOOD Vol. 144 (pp. 1304-1305). ELSEVIER.
DOI
2024 Shah, M., Hung, K., Baranwal, A., Price, Z., Al-Kali, A., Toop, C., . . . Hiwase, D. (2024). The 66th ASH Annual Meeting Abstract Abstracts. In BLOOD Vol. 144 (pp. 3214). ELSEVIER.
2024 Lim, K., Kutyna, M., Kan, W., Lopez, A. F., Brown, A., Yong, A. S. M., . . . Thomas, D. (2024). CBL Variants in Chronic Myelomonocytic Leukemia Exhibit a Complex Sub-Clone Architecture with a High Frequency of RING Domain Mutations Sufficient to Induce GM-CSF Hypersensitivity. In BLOOD Vol. 144 (pp. 3196-3197). ELSEVIER.
DOI
2024 Wechalekar, G., Cibich, A., Kutyna, M., Shanmuganathan, N., Sekaran, U. C., Singhal, D., . . . Hiwase, D. (2024). Clonal Architecture of Donor-Derived Leukemia/Clonal Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplant. In BLOOD Vol. 144 (pp. 4928-4929). FL, Orlando: ELSEVIER.
DOI
2024 Hiwase, D., Price, Z., Kok, C. H., Kutyna, M., Singhal, D., Shanmuganathan, N., . . . Scott, H. S. (2024). Pathogenic Germline Variants in the DNA Damage Repair Pathway Are Enriched in Patients with Hematologic Malignancies with Prior Exposure to Cytotoxic Therapies Compared to Patients with Multiple Cancers without Prior Exposure. In BLOOD Vol. 144 (pp. 4596-4597). FL, Orlando: ELSEVIER.
DOI
2021 Chhetri, R., Sharplin, K., Proudman, W., Kutyna, M. M., Nayar, S., Singhal, D., . . . Hiwase, D. (2021). Hypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype SubgroupsHypomethylating Therapy Does Not Improve Outcome of Therapy-Related Myeloid Neoplasm Including TP53 Mutated and Complex Karyotype Subgroups. In BLOOD Vol. 138 (pp. 3702-+). GA, Atlanta: ELSEVIER.
DOI WoS4
2021 Kutyna, M. M., Kok, C. H., Paton, S., Cakouros, D., Arthur, A., Hughes, T. P., . . . Hiwase, D. (2021). Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: AMER SOC HEMATOLOGY.
DOI WoS1
2021 Shah, M. V., Chhetri, R., Durani, U., Kutyna, M., Alkhateeb, H. B., Litzow, M. R., . . . Hiwase, D. (2021). T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: ELSEVIER.
DOI
2021 Hahn, C. N., Feurstein, S. K., Singhal, D., Kutyna, M. M., Chhetri, R., Wee, A., . . . Hiwase, D. (2021). Unexpected High Frequency of Pathogenic Germline Variants in Older Adults with Primary Myelodysplastic Syndrome. In BLOOD Vol. 138 (pp. 4 pages). GA, Atlanta: ELSEVIER.
DOI WoS1
2021 Choong, J., Kutyna, M. M., Chhetri, R., Moore, S., & Hiwase, D. (2021). Frequency of Chromosomal Translocations Are Significantly Higher in Therapy Related Myeloid Neoplasm As Compared to Primary MDS. In BLOOD Vol. 138 (pp. 3 pages). GA, Atlanta: ELSEVIER.
DOI WoS1
2019 Singhal, D., Hahn, C. N., Moma, L. D., Wee, L. Y. A., Chhetri, R., Babic, M., . . . Hiwase, D. K. (2019). Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy. In BLOOD Vol. 134 (pp. 3 pages). FL, Orlando: ELSEVIER.
DOI WoS1
2017 Singhal, D., Wee, A., Parker, W., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2017). Presence of Rare Germline Variants in Fanconi Anaemia Pathway Genes Confers a Poor Prognosis Comparable to <i>TP53</i> Mutations in Therapy-Related Myeloid Neoplasms. In BLOOD Vol. 130 (pp. 3 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS2
2017 Hahn, C. N., Wee, A., Babic, M., Feng, J., Wang, P., Kutyna, M. M., . . . Scott, H. S. (2017). Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms. In BLOOD Vol. 130 (pp. 2 pages). Atlanta, GA: AMER SOC HEMATOLOGY.
WoS3
2016 Singhal, D., Strupp, C., Chhetri, R., Kutyna, M., Wee, L., Nath, S., . . . Germing, U. (2016). RBC-transfusion dependency improves the prognostic value of the revised-IPSS in MDS patients: analysis of South Australian and Dusseldorf MDS registries. In Proceedings of the 58th Annual Meeting and Exposition of the American Society of Hematology, as published in Blood Vol. 128 (pp. 1998). San Diego, CA: American Society of Hematology.
2016 Singhal, D., Strupp, C., Chhetri, R., Kutyna, M. M., Wee, L. A., Nath, S. V., . . . Germing, U. (2016). RBC-Transfusion Dependency Improves the Prognostic Value of the Revised-IPSS in MDS Patients: Analysis of South Australian and Dusseldorf MDS Registries. In BLOOD Vol. 128 (pp. 6 pages). San Diego, CA: AMER SOC HEMATOLOGY.
2016 Singhal, D., Wee, L. A., Parker, W. T., Moore, S., Babic, M., Feng, J., . . . Hiwase, D. K. (2016). The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different. In BLOOD Vol. 128 (pp. 5 pages). San Diego, CA: AMER SOC HEMATOLOGY.
DOI
2015 Hahn, C. N., Babic, M., Schreiber, A. W., Kutyna, M. M., Wee, L. A., Brown, A. L., . . . Hiwase, D. (2015). Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome. In BLOOD Vol. 126 (pp. 4 pages). Orlando, FL: AMER SOC HEMATOLOGY.
DOI WoS3
2013 Hiwase, D. K., Kutyna, M. M., Chhetri, R., Howell, S., Harrison, P. B., Nath, S. V., . . . To, L. B. (2013). Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients. In BLOOD Vol. 122 (pp. 2 pages). New Orleans, LA: AMER SOC HEMATOLOGY.
DOI WoS5

Year Citation
2022 Shah, M. V., Hahn, C. N., Chhetri, R., Tran, E. N. H., & Hiwase, D. (2022). Integrated personalized prediction model identifies a subgroup of wild-type tp53therapy-related myeloid neoplasm patients with poor outcome. Poster session presented at the meeting of Blood. US: American Society of Hematology.
DOI
2019 Kutyna, M. M., Wee, A., Paton, S., Cakouros, D., Arthur, A., Chhetri, R., . . . Hiwase, D. K. (2019). Aberrant Bone Marrow Microenvironment in Therapy Related Myeloid Neoplasm (t-MN). Poster session presented at the meeting of BLOOD. FL, Orlando: ELSEVIER.
DOI WoS2
2018 Singhal, D., Wee, A., Kutyna, M. M., Babic, M., Chhetri, R., Parker, W., . . . Hiwase, D. K. (2018). Therapy-Related Myeloid Neoplasms (T-MN) and Primary MDS (PMDS) Patients with Very Low (VL) or Low (L) IPSS-R Score Share Clinical and Biological Characteristics and Have Similar Outcome. Poster session presented at the meeting of BLOOD. CA, San Diego: AMER SOC HEMATOLOGY.
DOI
2018 Chhetri, R., Wee, A., Sinha, R., Kutyna, M. M., Gupta, S., Nath, L., . . . Hiwase, D. K. (2018). Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome. Poster session presented at the meeting of BLOOD. San Diego, CA: AMER SOC HEMATOLOGY.
DOI WoS1
2017 Singhal, D., Wee, L. A., Babic, M., Parker, W., Moore, S., Feng, J., . . . Hiwase, D. (2017). THERAPY RELATED MYELOID NEOPLASMS (T-MN) SHOW HIGH MUTATION FREQUENCY AND A SPECTRUM DIFFERENT FROM PRIMARY MDS. Poster session presented at the meeting of LEUKEMIA RESEARCH. Valencia, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
DOI
2014 Hiwase, D. K., Singhal, D., Chhetri, R., Kutyna, M. M., Harrison, P. B., Nath, S. V., . . . To, L. B. (2014). Inclusion of RBC-Transfusion Dependency Can Improve the Prognostic Value of Revised-IPSS in MDS Patients. Poster session presented at the meeting of BLOOD. San Francisco, CA: AMER SOC HEMATOLOGY.

Year Citation
2023 Hong, L. E., Wechalekar, M. D., Kutyna, M. M., Small, A., Lim, K., Thompson-Peach, C., . . . Hiwase, D. K. (2023). Seronegative Rheumatoid Arthritis and Innate Immune Activation is Frequent in Myeloid Neoplasms with Isocitrate Dehydrogenase 1/2 Mutations.
DOI

Faculty of Health Sciences Divisional Scholarship and Dawes Supplementary Scholarship

Connect With Me

External Profiles

Other Links